Abstract
The ability of selective D-1 agonist and antagonist drugs to alter motor deficits and locomotor activity was studied in MPTP-treated common marmosets. Both the D-2 agonist quinpirole and the mixed D-1/D-2 agonist apomorphine reversed the motor impairments and induced locomotor activity. The D-1 antagonist SCH 23390 and the D-2 antagonist raclopride given alone further reduced motor function in MPTP-treated animals. The actions of quinpirole were potently and completely inhibited by raclopride but only partially and inconsistently by SCH 23390. In contrast, the effects of apomorphine were markedly but incompletely inhibited by both raclopride and SCH 23390. The D-1 agonist SKF 38393 alone caused a dose related reduction in motor activity. SKF 38393 weakly and partially inhibited the improvements in motor function produced by quinpirole but had a more pronounced effect on apomorphine induced motor activity. The induction of motor activity in MPTP treated common marmosets may separately involve both D-1 and D-2 receptors. Comparison with our previous data on the effect of the same drugs in normal common marmosets provides some evidence for a breakdown of linkage between D-1 and D-2 systems following MPTP treatment. The actions of SKF 38393 in MPTP-treated common marmosets contrasts with its ability to induce behavioural activation and a facilitation of D-2 mediated behaviour in rodents. SKF 38393 may not be the compound with which to delineate the role of D-1 receptors in primates.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abbott B, Starr BS, Starr MS (1991) CY 208–243 behaves as a typical D-1 agonist in the reserpine-treated mouse. Pharmacol Biochem Behav 38:259–263
Arnt J (1985) Hyperactivity induced by stimulation of separate D-1 and D-2 receptors in rats with bilateral 6-OHDA lesions. Life Sci 37:717–723
Arnt J, Perregaard J (1987) Synergistic interaction between dopamine D-1 and D-2 receptor agonists: circling behaviour of rats with hemitransection. Eur J Pharmacol 143:45–53
Barone P, Bankiewicz KS, Corsini GU, Kopin IJ, Chase TN (1987) Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology 37:1592–1595
Bédard PJ, Boucher R (1989) Effect of D-1 receptor stimulation in normal and MPTP monkeys. Neurosci Lett 104:233–228
Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD (1990) Differential effects of D-1 and D-2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 40:927–933
Braun AR, Chase T (1986) Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol 131:301–306
Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase TN (1987) Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 68:41–51
Breese GR, Criswell HE, McQuade RD, Iorio LC, Mueller RA (1990) Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors. J Pharmacol Exp Ther 252:558–567
Chandler CJ, Wohab W, Starr BS, Starr MS (1990) Motor depression: a new role for D1 receptors? Neuroscience 38:427–445
Clark D, White FJ (1987) Review: D1 dopamine receptor—the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1:347–388
Close SP, Marriott AS, Pay S (1985) Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. Br J Pharmacol 85:320–322
Close SP, Elliott PJ, Hayes AG, Marriott AS (1990) Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. Psychopharmacology 102:295–300
Gershanik O, Heikkila RE, Duvoisin RC (1983) Behavioural correlates of dopamine receptor activation. Neurology 33:1489–1492
Jackson DM, Hashizume M (1986) Bromocriptine induces marked locomtor stimulation in dopamine depleted mice when D-1 dopamine receptors are stimulated with SKF 38 393. Psychopharmacology 90:147–149
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96
LeWitt PA, Galloway MP (1987) Implications of D-1 agonism for antiparkinsonian therapeutics. In: Fahn S, Marsden CD, Calne D, Goldstein M (eds) Recent developments in Parkinson's disease. Macmillan, London, pp 75–89
Löschmann P-A, Smith LA, Lange KW, Jähnig P, Jenner P, Marsden CD (1991) Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets. Psychopharmacology 105:303–309
Mashurano M, Waddington JL (1986) Stereotyped behaviour in response to the selective D-2 receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK & F 38393. Neuropharmacology 25:947–949
Molloy AG, Waddington JL (1984) Dopaminergic behaviour stereospecifically promoted by the D1 agonist R-SK&F 38393 and selectivity blocked by the D1 antagonist SCH 23390. Psychopharmacology 82:409–410
Molloy AG, Waddington JL (1987) Assessment of grooming and other behavioural response to the D-1 dopamine receptor agonist SK&F 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology 92:164–168
Murray AM, Waddington JL (1989) Further evidence for two directions od D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502. Psychopharmacology 98:245–250
Nomoto M, Jenner P, Marsden CD (1985) The dopamine D-2 agonist LY 141 865, but not the D-1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci Lett 57:37–41
Nomoto M, Jenner P, Marsden CD (1988) The D-1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D-2 agonist LY 171555 in the MPTP-treated marmoset. Neurosci Lett 93:275–279
Pifl C, Reither H, Hornykiewicz O (1991) Lower efficacy of the dopamine D-1 agonist, SKF 38393, to stimulate adenyl cyclase activity in primate than in rodent striatum. Eur J Pharmacol 202:273–276
Pugh MT, O'Boyle KM, Molloy AG, Waddington JL (1985) Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU 24213. Psychopharmacology 87:308–312
Sonsalla PK, Manzino M, Heikkila E (1988) Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J Pharmacol Exp Ther 247:180–185
Starr MS, Starr BS (1989) Behavioural synergism between the dopamine agonists SKF 38 393 and LY 171 555 in dopamine-depleted mice: antagonism by sulpiride reveals only stimulant postsynaptic D-2 receptors. Pharmacol Biochem Behav 33:41–44
Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cAMP from rat neostriatum. Nature 294:366–368
Waddington JL, O'Boyle KM (1987) The D-1 dopamine receptor and the search for its functional role: from neurochemistry to behaviour. Rev Neurosci 1:157–184
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Löschmann, PA., Smith, L.A., Lange, K.W. et al. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology 109, 49–56 (1992). https://doi.org/10.1007/BF02245479
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245479